Abbott has launched a “next-generation” delivery system to streamline the electrode implantation process for its Proclaim DRG neurostimulation system. This advancement aims to improve ...

The company’s MySalvia system uses neuromodulation to alleviate the frequency and intensity of chronic migraines.

Chakravarthy is one of just a handful of San Diego physicians who have undergone specialized training to implant a new pain management device, Abbot's Proclaim™ DRG Neurostimulator System for ...

The DRG neurostimulator system consists of a tiny battery-operated generator that produces electrical pulses, ultra-thin wire leads for transmitting the currents and the patient controller that ...

The US Food and Drug Administration (FDA) has approved expanded MRI labeling for Abbott's Proclaim dorsal root ganglion (DRG) neurostimulator system in patients with complex regional pain syndrome ...

The digital health app will be compatible with Abbott’s Proclaim XR SCS System for patients with chronic pain in the trunk and limbs, as well as the Proclaim DRG Neurostimulation System for ...

AbbottABT recently announced the receipt of new national coverage for its dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna AET. Notably, Aetna plans to provide access to ...

Abbott has announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna, a leading health benefits company in the United ...

To provide the most user-friendly experience, the Proclaim DRG Neurostimulator System also utilizes an iPod touch'¡ mobile digital device as the system's patient controller communicates ...

ABBOTT PARK, Ill., May 2, 2022 /CSRwire/ - Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that ...

Healthcare & Pharmaceuticalscategory WHO declares mpox a global public health emergency for second time in two years 12:42 AM UTC Future of Healthcategory AstraZeneca's Imfinzi gets FDA priority ...